Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

March 5th 2025

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025

March 1st 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Dr Somaiah on the Role of Chemotherapy in Sarcomas

February 26th 2025

Neeta Somaiah, MD, discusses chemotherapy as the current mainstay of treatment in sarcoma subtypes and the emergence of immunotherapies in the space.

OH2 Demonstrates Tolerability and Combination Activity in Advanced Sarcoma

February 25th 2025

OH2 monotherapy was safe and treatment with the agent led to responses in combination with HX008 in locally advanced or metastatic sarcoma.

Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors

February 25th 2025

A panelist discusses how T-cell receptor (TCR) therapies are likely to evolve through innovations such as allogeneic approaches, enhanced manufacturing processes, identification of new target antigens, and potential combinations with other immunotherapies, which could expand their applicability across multiple sarcoma subtypes and other solid tumors while improving accessibility and efficacy.

Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options

February 25th 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) has shown encouraging response rates and durability of response in a heavily pretreated population where standard chemotherapy typically yields limited benefit, though direct comparisons are challenging because of the lack of randomized trials and the distinct patient populations treated with different therapeutic approaches.

Dr Randall on the Utility of Intraoperative Peripheral Margin Assessment in Soft Tissue Sarcomas

February 24th 2025

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma

February 24th 2025

The long-acting IL-7 agent efineptakin alfa was tolerable and led to responses in patients with Kaposi sarcoma, including in HIV-associated disease.

Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases

February 19th 2025

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma

February 18th 2025

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

Logistical Considerations for Delivering TCR Therapy to Patients

February 18th 2025

A panelist discusses how the logistical challenges of delivering T-cell receptor (TCR) therapy include coordinating lymphodepletion timing, managing the multiweek manufacturing process, ensuring proper handling and chain of custody of cellular products, and requiring specialized treatment centers with cell therapy expertise and infrastructure.

Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

February 18th 2025

A panelist discusses how the postinfusion challenges with afamitresgene autoleucel (afami-cel), such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, are generally manageable and time limited compared with the chronic cumulative toxicities seen with conventional chemotherapy regimens, though careful monitoring and prompt intervention remain essential.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumor

February 14th 2025

The FDA has approved vimseltinib for the treatment of patients with tenosynovial giant cell tumor.

Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas

February 12th 2025

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases

February 11th 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) therapy could potentially transform the treatment landscape for relapsed/refractory (R/R) synovial sarcoma by offering a targeted cellular therapy option with demonstrated efficacy in heavily pretreated patients, though its optimal positioning in the treatment sequence will need to be determined through additional clinical experience and data.

Approaches to First-Line Treatment for Synovial Sarcoma

February 11th 2025

A panelist discusses how the standard first-line approach for synovial sarcoma typically involves anthracycline-based chemotherapy (often doxorubicin with ifosfamide) while considering factors such as patient age, performance status, and tumor burden to determine the specific regimen intensity and duration.

Dr Livingston on the Addition of Hydroxychloroquine to Gemcitabine/Docetaxel in Osteosarcoma

February 10th 2025

John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.

Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing

February 4th 2025

A panelist discusses how although liquid biopsy offers potential advantages in terms of convenience and repeatability, tissue biopsy remains the current standard for MAGE-A4 testing because of the need for accurate protein expression assessment and established validation protocols, though ongoing research may eventually support complementary use of liquid biopsy approaches.

Best Practices for HLA and MAGE-A4 Testing

February 4th 2025

A panelist discusses how the main challenges in MAGE-A4 testing include optimizing the timing of both human leukocyte antigen (HLA) and MAGE-A4 expression testing, establishing standardized testing protocols across institutions, and ensuring adequate tissue availability for testing, while recommending early screening at diagnosis or first relapse to allow sufficient time for treatment planning if patients become eligible.